{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:59:39Z","timestamp":1793073579994,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T00:00:00Z","timestamp":1597795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T00:00:00Z","timestamp":1597795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The current epidemic of coronavirus disease-19 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) calls for the development of inhibitors of viral replication. Here, we performed a bioinformatic analysis of published and purported SARS-CoV-2 antivirals including imatinib mesylate that we found to suppress SARS-CoV-2 replication on Vero E6 cells and that, according to the published literature on other coronaviruses is likely to act on-target, as a tyrosine kinase inhibitor. We identified a cluster of SARS-CoV-2 antivirals with characteristics of lysosomotropic agents, meaning that they are lipophilic weak bases capable of penetrating into cells. These agents include cepharentine, chloroquine, chlorpromazine, clemastine, cloperastine, emetine, hydroxychloroquine, haloperidol, ML240, PB28, ponatinib, siramesine, and zotatifin (eFT226) all of which are likely to inhibit SARS-CoV-2 replication by non-specific (off-target) effects, meaning that they probably do not act on their \u2018official\u2019 pharmacological targets, but rather interfere with viral replication through non-specific effects on acidophilic organelles including autophagosomes, endosomes, and lysosomes. Imatinib mesylate did not fall into this cluster. In conclusion, we propose a tentative classification of SARS-CoV-2 antivirals into specific (on-target) versus non-specific (off-target) agents based on their physicochemical characteristics.<\/jats:p>","DOI":"10.1038\/s41419-020-02842-x","type":"journal-article","created":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T06:02:56Z","timestamp":1597816976000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["On-target versus off-target effects of drugs inhibiting the replication of SARS-CoV-2"],"prefix":"10.1038","volume":"11","author":[{"given":"Allan","family":"Sauvat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Ciccosanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Colavita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Di Rienzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Castilletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosaria","family":"Capobianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6081-9558","authenticated-orcid":false,"given":"Oliver","family":"Kepp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1596-0998","authenticated-orcid":false,"given":"Laurence","family":"Zitvogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4438-3325","authenticated-orcid":false,"given":"Gian Maria","family":"Fimia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Piacentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Kroemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,19]]},"reference":[{"key":"2842_CR1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.15698\/cst2020.04.216","volume":"4","author":"D Raoult","year":"2020","unstructured":"Raoult, D., Zumla, A., Locatelli, F., Ippolito, G. & Kroemer, G. Coronavirus infections: epidemiological, clinical and immunological features and hypotheses. Cell Stress 4, 66\u201375 (2020).","journal-title":"Cell Stress"},{"key":"2842_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2332-7","author":"D Bojkova","year":"2020","unstructured":"Bojkova, D. et al. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets. Nature https:\/\/doi.org\/10.1038\/s41586-020-2332-7 (2020).","journal-title":"Nature"},{"key":"2842_CR3","first-page":"16","volume":"18","author":"R Guha","year":"2007","unstructured":"Guha, R. Chemical informatics functionality in R. 2007 18, 16 (2007).","journal-title":"2007"},{"key":"2842_CR4","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1093\/bioinformatics\/btn307","volume":"24","author":"Y Cao","year":"2008","unstructured":"Cao, Y., Charisi, A., Cheng, L. C., Jiang, T. & Girke, T. ChemmineR: a compound mining framework for R. Bioinformatics 24, 1733\u20131734 (2008).","journal-title":"Bioinformatics"},{"key":"2842_CR5","doi-asserted-by":"publisher","unstructured":"Yao, X. et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa237 (2020).","DOI":"10.1093\/cid\/ciaa237"},{"key":"2842_CR6","doi-asserted-by":"publisher","first-page":"m1849","DOI":"10.1136\/bmj.m1849","volume":"369","author":"W Tang","year":"2020","unstructured":"Tang, W. et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ 369, m1849 (2020).","journal-title":"BMJ"},{"key":"2842_CR7","doi-asserted-by":"publisher","first-page":"m1844","DOI":"10.1136\/bmj.m1844","volume":"369","author":"M Mahevas","year":"2020","unstructured":"Mahevas, M. et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ 369, m1844 (2020).","journal-title":"BMJ"},{"key":"2842_CR8","doi-asserted-by":"publisher","unstructured":"Boulware, D. R. et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. New Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2016638 (2020).","DOI":"10.1056\/NEJMoa2016638"},{"key":"2842_CR9","doi-asserted-by":"publisher","unstructured":"Liu, W. et al. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARSCoV-2 and other acute viral infections: a systematic review and meta-analysis. Can. Med. Assoc. J. https:\/\/doi.org\/10.1503\/cmaj.200647 (2020).","DOI":"10.1503\/cmaj.200647"},{"key":"2842_CR10","doi-asserted-by":"publisher","first-page":"3927","DOI":"10.1038\/sj.onc.1206622","volume":"22","author":"P Boya","year":"2003","unstructured":"Boya, P. et al. Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine. Oncogene 22, 3927\u20133936 (2003).","journal-title":"Oncogene"},{"key":"2842_CR11","doi-asserted-by":"publisher","first-page":"6434","DOI":"10.1038\/onc.2008.310","volume":"27","author":"P Boya","year":"2008","unstructured":"Boya, P. & Kroemer, G. Lysosomal membrane permeabilization in cell death. Oncogene 27, 6434\u20136451 (2008).","journal-title":"Oncogene"},{"key":"2842_CR12","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/0028-3908(87)90029-3","volume":"26","author":"I Briggs","year":"1987","unstructured":"Briggs, I. & Barnes, J. C. Actions of opioids on the dorsal root potential of the isolated spinal cord preparation of the neonate rat. Neuropharmacology 26, 469\u2013475 (1987).","journal-title":"Neuropharmacology"},{"key":"2842_CR13","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.abb3405","volume":"368","author":"L Zhang","year":"2020","unstructured":"Zhang, L. et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors. Science 368, 409\u2013412 (2020).","journal-title":"Science"},{"key":"2842_CR14","doi-asserted-by":"publisher","unstructured":"Yuan, S. et al. Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system. Pharmacol. Res. https:\/\/doi.org\/10.1016\/j.phrs.2020.104960 (2020).","DOI":"10.1016\/j.phrs.2020.104960"},{"key":"2842_CR15","doi-asserted-by":"publisher","unstructured":"Adeoye, A. O., Oso, B. J., Olaoye, I. F., Tijjani, H. & Adebayo, A. I. Repurposing of chloroquine and some clinically approved antiviral drugs as effective therapeutics to prevent cellular entry and replication of coronavirus. J. Biomol. Struct. Dyn. https:\/\/doi.org\/10.1080\/07391102.2020.1765876 (2020).","DOI":"10.1080\/07391102.2020.1765876"},{"key":"2842_CR16","doi-asserted-by":"publisher","unstructured":"Sheahan, T. P. et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.abb5883 (2020).","DOI":"10.1126\/scitranslmed.abb5883"},{"key":"2842_CR17","doi-asserted-by":"publisher","unstructured":"Huang, J., Song, W., Huang, H. & Sun, Q. Pharmacological therapeutics targeting RNA-dependent RNA polymerase, proteinase and spike protein: from mechanistic studies to clinical trials for COVID-19. J. Clin. Med. https:\/\/doi.org\/10.3390\/jcm9041131 (2020).","DOI":"10.3390\/jcm9041131"},{"key":"2842_CR18","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1097\/CM9.0000000000000797","volume":"133","author":"HH Fan","year":"2020","unstructured":"Fan, H. H. et al. Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model. Chin. Med. J. 133, 1051\u20131056 (2020).","journal-title":"Chin. Med. J."},{"key":"2842_CR19","first-page":"4539","volume":"24","author":"SA Meo","year":"2020","unstructured":"Meo, S. A., Klonoff, D. C. & Akram, J. Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19. Eur. Rev. Med. Pharmacol. Sci. 24, 4539\u20134547 (2020).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"2842_CR20","doi-asserted-by":"publisher","unstructured":"Plaze, M. et al. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study]. L\u2019Encephale https:\/\/doi.org\/10.1016\/j.encep.2020.04.010 (2020).","DOI":"10.1016\/j.encep.2020.04.010"},{"key":"2842_CR21","doi-asserted-by":"publisher","first-page":"104786","DOI":"10.1016\/j.antiviral.2020.104786","volume":"178","author":"KT Choy","year":"2020","unstructured":"Choy, K. T. et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antivir. Res. 178, 104786 (2020).","journal-title":"Antivir. Res."},{"key":"2842_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-020-01342-w","volume":"17","author":"CC Li","year":"2020","unstructured":"Li, C. C. & Wang, X. J. Three kinds of treatment with Homoharringtonine, Hydroxychloroquine or shRNA and their combination against coronavirus PEDV in vitro. Virol. J. 17, 71 (2020).","journal-title":"Virol. J."},{"key":"2842_CR23","doi-asserted-by":"publisher","first-page":"104787","DOI":"10.1016\/j.antiviral.2020.104787","volume":"178","author":"L Caly","year":"2020","unstructured":"Caly, L., Druce, J. D., Catton, M. G., Jans, D. A. & Wagstaff, K. M. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antivir. Res. 178, 104787 (2020).","journal-title":"Antivir. Res."},{"key":"2842_CR24","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1146\/annurev.immunol.22.012703.104753","volume":"22","author":"S Wong","year":"2004","unstructured":"Wong, S. & Witte, O. N. The BCR-ABL story: bench to bedside and back. Annu. Rev. Immunol. 22, 247\u2013306 (2004).","journal-title":"Annu. Rev. Immunol."},{"key":"2842_CR25","doi-asserted-by":"publisher","first-page":"8924","DOI":"10.1128\/JVI.01429-16","volume":"90","author":"CM Coleman","year":"2016","unstructured":"Coleman, C. M. et al. Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and middle east respiratory syndrome coronavirus fusion. J. Virol. 90, 8924\u20138933 (2016).","journal-title":"J. Virol."},{"key":"2842_CR26","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1016\/0006-2952(74)90174-9","volume":"23","author":"C de Duve","year":"1974","unstructured":"de Duve, C. et al. Commentary. Lysosomotropic agents. Biochem. Pharmacol. 23, 2495\u20132531 (1974).","journal-title":"Biochem. Pharmacol."},{"key":"2842_CR27","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1128\/MCB.25.3.1025-1040.2005","volume":"25","author":"P Boya","year":"2005","unstructured":"Boya, P. et al. Inhibition of macroautophagy triggers apoptosis. Mol. Cell. Biol. 25, 1025\u20131040 (2005).","journal-title":"Mol. Cell. Biol."},{"key":"2842_CR28","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/j.2042-7158.1986.tb04640.x","volume":"38","author":"DJ Morgan","year":"1986","unstructured":"Morgan, D. J., Thiel, W. J., La Rosa, C. & Mather, L. E. Variability of the blood\/plasma concentration ratio of pethidine. J. Pharm. Pharmacol. 38, 557\u2013558 (1986).","journal-title":"J. Pharm. Pharmacol."},{"key":"2842_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0658-8","volume":"13","author":"S Apolloni","year":"2016","unstructured":"Apolloni, S., Fabbrizio, P., Amadio, S. & Volonte, C. Actions of the antihistaminergic clemastine on presymptomatic SOD1-G93A mice ameliorate ALS disease progression. J. Neuroinflammation 13, 191 (2016).","journal-title":"J. Neuroinflammation"},{"key":"2842_CR30","doi-asserted-by":"publisher","first-page":"5858","DOI":"10.1021\/jm200591t","volume":"54","author":"C Abate","year":"2011","unstructured":"Abate, C. et al. Fluorescent derivatives of sigma receptor ligand 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) as a tool for uptake and cellular localization studies in pancreatic tumor cells. J. Med. Chem. 54, 5858\u20135867 (2011).","journal-title":"J. Med. Chem."},{"key":"2842_CR31","doi-asserted-by":"publisher","first-page":"8975","DOI":"10.1158\/0008-5472.CAN-05-0269","volume":"65","author":"MS Ostenfeld","year":"2005","unstructured":"Ostenfeld, M. S. et al. Effective tumor cell death by sigma-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress. Cancer Res. 65, 8975\u20138983 (2005).","journal-title":"Cancer Res."},{"key":"2842_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.361","volume":"4","author":"MH Cesen","year":"2013","unstructured":"Cesen, M. H., Repnik, U., Turk, V. & Turk, B. Siramesine triggers cell death through destabilisation of mitochondria, but not lysosomes. Cell Death Dis. 4, e818 (2013).","journal-title":"Cell Death Dis."},{"key":"2842_CR33","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3390\/ijms17030404","volume":"17","author":"A Canfran-Duque","year":"2016","unstructured":"Canfran-Duque, A. et al. First-generation antipsychotic haloperidol alters the functionality of the late endosomal\/lysosomal compartment in vitro. Int. J. Mol. Sci. 17, 404 (2016).","journal-title":"Int. J. Mol. Sci."},{"key":"2842_CR34","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.neuroscience.2012.02.035","volume":"209","author":"J Park","year":"2012","unstructured":"Park, J. et al. Haloperidol and clozapine block formation of autophagolysosomes in rat primary neurons. Neuroscience 209, 64\u201373 (2012).","journal-title":"Neuroscience"},{"key":"2842_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082481","volume":"8","author":"R Ashoor","year":"2013","unstructured":"Ashoor, R., Yafawi, R., Jessen, B. & Lu, S. The contribution of lysosomotropism to autophagy perturbation. PLoS ONE 8, e82481 (2013).","journal-title":"PLoS ONE"},{"key":"2842_CR36","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.phrs.2016.05.004","volume":"110","author":"Y Li","year":"2016","unstructured":"Li, Y. et al. A cell-based quantitative high-throughput image screening identified novel autophagy modulators. Pharmacol. Res. 110, 35\u201349 (2016).","journal-title":"Pharmacol. Res."},{"key":"2842_CR37","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1083\/jcb.123.5.1107","volume":"123","author":"LH Wang","year":"1993","unstructured":"Wang, L. H., Rothberg, K. G. & Anderson, R. G. Mis-assembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation. J. Cell Biol. 123, 1107\u20131117 (1993).","journal-title":"J. Cell Biol."},{"key":"2842_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2017.10.001","volume":"412","author":"ZH Tang","year":"2018","unstructured":"Tang, Z. H. et al. Identification of a novel autophagic inhibitor cepharanthine to enhance the anti-cancer property of dacomitinib in non-small cell lung cancer. Cancer Lett. 412, 1\u20139 (2018).","journal-title":"Cancer Lett."},{"key":"2842_CR39","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF02889337","volume":"15","author":"J Kovacs","year":"1974","unstructured":"Kovacs, J. & Rez, G. Prevention of induced autophagy by emetine in exocrine cells of mouse pancreas and seminal vesicle. Virchows Arch. B Cell Pathol. 15, 209\u2013216 (1974).","journal-title":"Virchows Arch. B Cell Pathol."},{"key":"2842_CR40","doi-asserted-by":"publisher","first-page":"101663","DOI":"10.1016\/j.tmaid.2020.101663","volume":"34","author":"P Gautret","year":"2020","unstructured":"Gautret, P. et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study. Travel Med. Infect. Dis. 34, 101663 (2020).","journal-title":"Travel Med. Infect. Dis."},{"key":"2842_CR41","doi-asserted-by":"publisher","unstructured":"Rogado, J. et al. Covid-19 transmission, outcome and associated risk factors in cancer patients at the first month of the pandemic in a Spanish hospital in Madrid. Clin. Transl. Oncol. https:\/\/doi.org\/10.1007\/s12094-020-02381-z (2020).","DOI":"10.1007\/s12094-020-02381-z"},{"key":"2842_CR42","doi-asserted-by":"publisher","unstructured":"Park, S. J. et al. Antiviral efficacies of FDA-approved drugs against SARS-CoV-2 infection in ferrets. mBio https:\/\/doi.org\/10.1128\/mBio.01114-20 (2020).","DOI":"10.1128\/mBio.01114-20"},{"key":"2842_CR43","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00228-004-0811-7","volume":"60","author":"EM Strachan","year":"2004","unstructured":"Strachan, E. M., Kelly, C. A. & Bateman, D. N. Electrocardiogram and cardiovascular changes in thioridazine and chlorpromazine poisoning. Eur. J. Clin. Pharmacol. 60, 541\u2013545 (2004).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"2842_CR44","doi-asserted-by":"publisher","unstructured":"Campleman, S. L. et al. Drug-specific risk of severe QT prolongation following acute drug overdose. Clin. Toxicol. https:\/\/doi.org\/10.1080\/15563650.2020.1746330 (2020).","DOI":"10.1080\/15563650.2020.1746330"},{"key":"2842_CR45","doi-asserted-by":"publisher","unstructured":"Mercuro, N. J. et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. https:\/\/doi.org\/10.1001\/jamacardio.2020.1834 (2020).","DOI":"10.1001\/jamacardio.2020.1834"},{"key":"2842_CR46","doi-asserted-by":"publisher","unstructured":"Grein, J. et al. Compassionate use of remdesivir for patients with severe Covid-19. New Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2007016 (2020).","DOI":"10.1056\/NEJMoa2007016"},{"key":"2842_CR47","doi-asserted-by":"publisher","unstructured":"Beigel, J. H. et al. Remdesivir for the treatment of Covid-19 - preliminary report. New Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2007764 (2020).","DOI":"10.1056\/NEJMoa2007764"},{"key":"2842_CR48","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1099\/jgv.0.001047","volume":"99","author":"JM Sisk","year":"2018","unstructured":"Sisk, J. M., Frieman, M. B. & Machamer, C. E. Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors. J. Gen. Virol. 99, 619\u2013630 (2018).","journal-title":"J. Gen. Virol."},{"key":"2842_CR49","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1146\/annurev-med-043010-091813","volume":"63","author":"H Joensuu","year":"2012","unstructured":"Joensuu, H. & DeMatteo, R. P. The management of gastrointestinal stromal tumors: a model for targeted and multidisciplinary therapy of malignancy. Annu. Rev. Med. 63, 247\u2013258 (2012).","journal-title":"Annu. Rev. Med."},{"key":"2842_CR50","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/nrclinonc.2016.59","volume":"13","author":"L Gorkin","year":"2016","unstructured":"Gorkin, L. & Kantarjian, H. Targeted therapy: generic imatinib - impact on frontline and salvage therapy for CML. Nat. Rev. Clin. Oncol. 13, 270\u2013272 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2842_CR51","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nrclinonc.2016.41","volume":"13","author":"L Zitvogel","year":"2016","unstructured":"Zitvogel, L., Rusakiewicz, S., Routy, B., Ayyoub, M. & Kroemer, G. Immunological off-target effects of imatinib. Nat. Rev. Clin. Oncol. 13, 431\u2013446 (2016).","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-02842-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-02842-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-02842-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T15:08:35Z","timestamp":1670252915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-02842-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,19]]},"references-count":51,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8]]}},"alternative-id":["2842"],"URL":"https:\/\/doi.org\/10.1038\/s41419-020-02842-x","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,19]]},"assertion":[{"value":"8 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"656"}}